Drug Combination Details
| General Information of the Combination (ID: C76104) | |||||
|---|---|---|---|---|---|
| Name | Epigallocatechin gallate NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [2] | |||
|
Osteosarcoma
[ICD-11: 2B51]
|
Investigative | [3] | |||
|
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [4] | |||
|
Colon cancer
[ICD-11: 2B90]
|
Investigative | [4] | |||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [4] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
EGCG inhibited DOX-induced overexpression of P-gp through the coordinate inhibitory action on MEK/ERK and PI3K/Akt signaling pathways. | |||||
| Experiment 2 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | ||
| In-vivo Model | The nude mice were subcutaneously inoculated with cell suspension containing 1*107 Hep3B cells per mouse in the right side fossa axillaries. | |||||
| Experimental
Result(s) |
EGCG emerges as a chemotherapeutic augmenter and synergistically enhances DOX anticancer effects involving autophagy inhibition in HCC. | |||||
| Experiment 3 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
| IBC-10a | Prostate cancer | Homo sapiens | ||||
| PCa-20a | Prostate cancer | Homo sapiens | ||||
| In-vivo Model | Single-cell suspensions of PC-3ML cells (1*106 cells) at passage 10 were injected intraperitoneally in 5- to 6-week-old male CB17-SCID mice. | |||||
| Experimental
Result(s) |
EGCG in combination with low levels of Dox had a synergistic effect in blocking tumor cell growth. | |||||
| Experiment 4 Reporting the Effect of This Combination | [3] | |||||
| In-vitro Model | U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | ||
| SaOS-2 | CVCL_0548 | Osteosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| BxPC-3 | CVCL_0186 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
| HCT 15 | CVCL_0292 | Colon adenocarcinoma | Homo sapiens | |||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| NCI-H358 | CVCL_1559 | Lung adenocarcinoma | Homo sapiens | |||
| A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
EGCG sensitizes chemotherapeutic-induced cytotoxicity by targeting the ERK pathway in multiple cancer cell lines. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [6] | |||||
| Biological
Regulation |
Up-regulation | DOX accumulation | ||||
| In-vitro Model | KB-A1 | CVCL_1D82 | Human oral epidermoid carcinoma | Homo sapiens | ||
| In-vivo Model | About 5 x106 cells were subcutaneously injected into the right flank of the athymic male nude mice. | |||||
| Experimental
Result(s) |
EGCG could chemosensitize resistant tumor cells to DOX in vivo through an increase in the accumulation of DOX in the tumors. | |||||
